Furthermore, it has been demonstrated that AZD2858 (a GSK3β inhibitor) induces the nuclear accumulation of β-catenin, reducing the proliferation and invasion in glioma cells through of upregulation of p53, which regulates the transcription of p21, the Fas ligand, and caspase-3 31, as well as the downregulation of proteins involved in cell adhesion and cell migration, like collagen type I, Laminin, CD44, and fibronectin 31. Here, GSK3B is linked to central nervous system cancer.